Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …

Adoptive cell transfer after host preconditioning by lymphodepletion represents an important
advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment …

Lymphodepletion with total body irradiation (TBI) increases the efficacy of adoptively
transferred tumor-specific CD8+ T cells by depleting inhibitory lymphocytes and increasing …

Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective
adoptive cellular immunotherapy for the treatment of a number of cancers. The …

Lymphodepletion followed by adoptive cell transfer (ACT) of autologous, tumor-reactive T
cells boosts antitumor immunotherapeutic activity in mouse and in humans. In the most …

Mesenchymal stromal cells or mesenchymal stem cells (MSCs) have captured considerable
scientific and public interest because of their potential to limit physical and immune injury, to …

Dendritic cells (DCs) are a heterogeneous fraction of rare hematopoietic cells that coevolved
with the formation of the adaptive immune system. DCs efficiently process and present …

The year 2009 marked the fiftieth anniversary of the first successful allogeneic
haematopoietic stem cell transplant (HSCT). The field of HSCT has pioneered some of the …

Graft-versus-host disease (GVHD) is caused by alloreactive donor T cells that trigger host
tissue injury. GVHD develops over weeks or months, but how this immune response is …

In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive
conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in …